検索結果

g approval in Japan as of December 22, 2025. Avarept® Ophthalmic suspension 0.3% represents a novel therapy for DED with Transient Receptor Potential cation channel subfamily V member 1 (TRPV1)*1 anta...

Research and Development System | Research & Development | SENJU Pharmaceutica

through a flexible concept without adhering to a conventional framework or stereotypes. Looking at the future and quickly developing safe drugs that are needed are our goals as well as our wishes. Me...

临床试验信息 | 研究与开发 | 千寿制药株式会社

clinical trials sponsored by SENJU PHARMACEUTICAL Co., Ltd. (hereinafter referred to as “SENJU”) to the public including patients and their families, in order to ensure the transparency of clinical tr...

Clinical Trial Summaries | Research & Development | SENJU Pharmaceutica

clinical trials sponsored by SENJU PHARMACEUTICAL Co., Ltd. (hereinafter referred to as “SENJU”) to the public including patients and their families, in order to ensure the transparency of clinical tr...

Clinical Trial Summaries | Research & Development | SENJU Pharmaceutica

clinical trials sponsored by SENJU PHARMACEUTICAL Co., Ltd. (hereinafter referred to as “SENJU”) to the public including patients and their families, in order to ensure the transparency of clinical tr...